Rattlesnake venom is primarily hemotoxic, meaning it attacks blood cells, disrupts clotting, and damages tissue. But some rattlesnake species and even specific geographic populations carry significant neurotoxic components in their venom. So the short answer is: most rattlesnake venom is not purely a neurotoxin, but neurotoxins are present in several species and can be the dominant threat in a few.
What Rattlesnake Venom Is Made Of
Rattlesnake venom is a complex cocktail. Researchers have identified 64 families and subfamilies of proteins across rattlesnake species. The three most common groups are metalloproteinases, serine proteases, and phospholipases A2. Each class does different damage.
Metalloproteinases are the heavy hitters behind the classic rattlesnake bite: they disrupt blood clotting, break down tissue, and cause severe bleeding and hemorrhage within minutes. This is the hemotoxic activity most people associate with rattlesnakes. Serine proteases compound those effects by further interfering with coagulation.
Phospholipases A2, however, pull double duty. Beyond their roles in causing swelling, muscle damage, and interfering with clotting, this protein family is also responsible for neurotoxic effects. In species where phospholipase A2 is especially abundant or potent, the venom shifts from primarily blood-destroying to significantly nerve-disrupting.
How Rattlesnake Neurotoxins Attack Nerves
When rattlesnake venom does contain neurotoxins, they almost always act at the presynaptic site, the nerve ending that releases chemical signals to muscles. These toxins block the release of acetylcholine, the messenger molecule that tells muscles to contract. Without that signal, muscles go silent. This is classified as beta-neurotoxic activity.
The process unfolds in a characteristic three-phase pattern. First, nerve signaling briefly increases (sometimes causing muscle twitching or fasciculations). Then signaling drops. Finally, the nerve-to-muscle connection shuts down entirely and becomes irreversible without treatment. The end result is progressive paralysis, starting with the muscles of the face and eyes and potentially advancing to the muscles that control breathing.
This is different from cobras and other elapid snakes, which tend to use postsynaptic neurotoxins. Those block the receiving end of the signal, jamming the receptor on the muscle side. Rattlesnake neurotoxins instead prevent the signal from being sent in the first place.
Which Rattlesnakes Have Neurotoxic Venom
Three North American rattlesnake species are most associated with clinically significant neurotoxicity.
The Mojave rattlesnake (Crotalus scutulatus) is the most well-known neurotoxic rattlesnake. Its signature compound, called Mojave toxin, is a phospholipase A2 neurotoxin that blocks nerve-to-muscle transmission. Not every Mojave rattlesnake has the same venom profile. Some populations produce venom that is predominantly neurotoxic, others predominantly hemotoxic, and some carry both.
The Southern Pacific rattlesnake (Crotalus helleri) has gained attention for causing neurological symptoms in bite victims. A case series documented seven patients with significant neurotoxicity after bites from this species, including slurred speech, loss of coordination, and involuntary muscle rippling. Clinicians in Southern California are increasingly aware that this species can cause nerve-related problems alongside typical tissue damage.
The timber rattlesnake (Crotalus horridus) is perhaps the most interesting example because its venom varies dramatically by geography. Researchers have classified timber rattlesnake venom into four types based on location:
- Type A: Primarily neurotoxic, with presynaptic activity similar to the Mojave rattlesnake. Found in populations along the Georgia-north Florida border.
- Type B: Primarily hemotoxic, affecting blood clotting and tissue. Found in northern and midwestern U.S. populations and parts of north Florida.
- Type A+B: A combination of both neurotoxic and hemotoxic effects. Found along Florida’s northern border, extending south into central Florida.
- Type C: A distinct additional profile identified in certain populations.
This means two timber rattlesnakes living a few hundred miles apart can deliver fundamentally different types of envenomation. A bite in Georgia could produce neurological symptoms, while a bite in Pennsylvania is far more likely to cause bleeding and swelling.
Why the Same Species Can Have Different Venom
Venom composition is shaped by what a snake eats. Venom is an ecological tool, and its makeup tends to coevolve with the physiology of prey animals in a given region. Populations that feed on different prey over many generations can develop different venom profiles through gene duplication and natural selection favoring whichever toxins work best on local food sources. This is why geographic location matters so much when predicting what a rattlesnake bite will do.
What Neurotoxic Symptoms Look Like
A bite from a neurotoxic rattlesnake can look deceptively mild at first. Local swelling and pain may be less dramatic than a purely hemotoxic bite, which sometimes leads to underestimation of the severity. The neurological effects tend to appear later.
The earliest sign of neurotoxicity is typically drooping eyelids (ptosis) and difficulty moving the eyes. In elapid bites, these can appear as quickly as 15 minutes, though onset from rattlesnake neurotoxins may be slower, sometimes delayed by several hours. Symptoms can progress to difficulty speaking, trouble swallowing, muscle weakness, and in severe cases, paralysis of the breathing muscles. Respiratory failure is the life-threatening endpoint.
This delayed onset is part of what makes neurotoxic rattlesnake bites tricky. Someone bitten by a Mojave rattlesnake might initially feel relatively fine compared to a person bitten by a Western diamondback, only to develop serious symptoms hours later.
How Antivenom Handles Neurotoxic Venom
Two antivenoms are approved in the U.S. for rattlesnake bites. CroFab, available since 2000, is manufactured using venom from four species, including the Mojave rattlesnake, which means it does contain antibodies targeting neurotoxic components. Anavip, approved in 2018, covers North American rattlesnake envenomations as well.
The challenge is that neurotoxic effects from rattlesnake bites are sometimes difficult to control with antivenom, even when the right product is administered promptly. Once the neurotoxin has bound to nerve terminals and the damage has progressed to irreversible blockade, antivenom cannot undo what has already happened. It can only neutralize circulating toxin that hasn’t yet reached its target. This is one reason early treatment after any rattlesnake bite is important, but especially so when neurotoxic species are involved.